This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
T. Rowe Price (TROW) Stock Gains 2.1% as November AUM Increases
by Zacks Equity Research
T. Rowe Price (TROW) records AUM worth $1.34 trillion for November 2022, reflecting a rise of 4.7% from the previous month.
Invesco (IVZ) November AUM Rises 5.7% on Favorable Markets
by Zacks Equity Research
Invesco (IVZ) records a 5.7% sequential rise in preliminary assets under management for November 2022.
AllianceBernstein and Societe Generale Plan to Form a JV
by Zacks Equity Research
AllianceBernstein (AB) and Societe Generale (SCGLY) decide to form a JV by combining their cash equities and equity research businesses.
T. Rowe Price (TROW) Gains 17% on October AUM Rise to $1.28T
by Zacks Equity Research
T. Rowe Price (TROW) witnesses an improvement in October AUM on the back of favorable market performance.
Lazard's (LAZ) October AUM Rises 3.4% on Market Appreciation
by Zacks Equity Research
Market appreciation and favorable FX movements aid Lazard's (LAZ) October AUM balance.
Virtus Investment (VRTS) Stock Gains 7.8% on October AUM Rise
by Zacks Equity Research
Virtus Investment (VRTS) records an AUM balance of $149.5 billion for the end of October 2022, which represents a rise of 3.1% from the end of the previous month.
Invesco (IVZ) October AUM Rises 2.8% on Favorable Markets
by Zacks Equity Research
Invesco (IVZ) records a 2.8% sequential rise in preliminary assets under management for October 2022.
AllianceBernstein (AB) Stock Up 1.7% as October AUM Rises
by Zacks Equity Research
AllianceBernstein's (AB) October AUM balance improves on the back of solid market performance.
Implied Volatility Surging for AllianceBernstein (AB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AllianceBernstein (AB) stock based on the movements in the options market lately.
Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE
by Zacks Equity Research
Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE have been highlighted in this Screen of The Week article.
3 Stocks for Higher Returns as New Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), AllianceBernstein (AB) and ALLETE (ALE).
Lazard's (LAZ) August AUM Slips 3.6% on Market Depreciation
by Zacks Equity Research
Market depreciation, unfavorable FX movements and net outflows hurt Lazard's (LAZ) August AUM balance.
Invesco's (IVZ) August AUM Down on Unfavorable Market Returns
by Zacks Equity Research
Market depreciation, unfavorable FX movements and non-management fee-earning net outflows hurt Invesco's (IVZ) August AUM balance as it falls 2.3% from the prior month.
AllianceBernstein (AB) Stock Up 2.3% as July AUM Rises 6.5%
by Zacks Equity Research
Market appreciation and the acquisition of CarVal Investors aid AllianceBernstein's (AB) July AUM balance as it rises 6.5% from the prior month.
AllianceBernstein (AB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AllianceBernstein (AB) closed the most recent trading day at $43, moving +0.37% from the previous trading session.
AllianceBernstein (AB) Witnesses Marginal Rise in May AUM
by Zacks Equity Research
AllianceBernstein (AB) records month-end AUM of $687 billion in May 2022, up marginally from the end of the prior month.
Equitable Holdings (EQH) Cheers Investors With 11% Dividend Hike
by Zacks Equity Research
Based on the increased rate, Equitable Holdings' (EQH) annual dividend comes to 80 cents per share.
AllianceBernstein (AB) Stock Down as April AUM Declines 6.8%
by Zacks Equity Research
Dismal market performance and outflows lead to a decline in AllianceBernstein's (AB) April AUM balance.
Franklin Resources (BEN) Completes Lexington Partners Buyout
by Zacks Equity Research
Franklin (BEN) completes the acquisition of Lexington Partners L.P. in a cash deal of $1.75 billion to boost its alternative asset business.
Equitable Holdings (EQH) Arm to Acquire CarVal for $750M
by Zacks Equity Research
Equitable Holdings (EQH) expects the CarVal Investors acquisition to close in the second quarter of this year.
AllianceBernstein (AB) to Acquire CarVal Investors for $750M
by Zacks Equity Research
AllianceBernstein (AB) will strengthen private market capabilities and market position with the acquisition of CarVal, a global private alternatives investment manager, for $750 million.
AllianceBernstein (AB) February AUM Down on Unfavorable Markets
by Zacks Equity Research
AllianceBernstein's (AB) AUM balance for February declines on market depreciation, while net inflows offer some support.
AllianceBernstein (AB) January AUM Down on Market Depreciation
by Zacks Equity Research
AllianceBernstein's (AB) preliminary AUM for month-end January 2022 of $751 billion is down 3.6% from the previous month. The decline is mainly due to market depreciation.
Has AllianceBernstein (AB) Outpaced Other Finance Stocks This Year?
by Zacks Equity Research
Here is how AllianceBernstein (AB) and Assurant (AIZ) have performed compared to their sector so far this year.
Best Income Stocks to Buy for February 14th
by Zacks Equity Research
AB, TSE, and DHI made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 14, 2022